HOX1A Antibody

What is HOXA1 and what biological functions does it regulate?

HOXA1 is a sequence-specific transcription factor that regulates multiple developmental processes including brainstem, inner and outer ear, abducens nerve and cardiovascular development and morphogenesis as well as cognition and behavior . It is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis, primarily acting on anterior body structures. HOXA1 appears to be involved in the maintenance and/or generation of hindbrain segments and activates transcription in the presence of PBX1A and PKNOX1 . Also known as HOX1F or Homeobox protein Hox-A1, this protein has been identified as a critical developmental regulator whose dysregulation is associated with several pathological conditions.

What are the optimal applications for HOXA1 antibodies in experimental research?

Based on validated research applications, HOXA1 antibodies are primarily suitable for Western Blot (WB) and Immunocytochemistry/Immunofluorescence (ICC/IF) techniques using human samples . When selecting an antibody for research, consider whether the specific application has been validated. For instance, the ab168179 Mouse Polyclonal HOXA1 antibody has been cited in publications for these applications and reacts with human samples . For optimal results, researchers should follow manufacturer-recommended protocols and dilutions, with appropriate positive and negative controls to validate specificity in their experimental system.

How is HOXA1 protein localized within cells, and what implications does this have for detection methods?

HOXA1 protein immunostaining is primarily localized in the cell nucleus, though it can be widely distributed throughout cancer nests in tumor samples . This nuclear localization is consistent with its function as a transcription factor. When designing experiments to detect HOXA1, nuclear extraction protocols are crucial for efficient protein isolation. For immunohistochemistry or immunofluorescence applications, nuclear counterstaining (such as with DAPI or hematoxylin) is important to confirm the nuclear localization pattern. The percentage of HOXA1-positive cells and HOXA1-positive area measurements can provide quantitative data for comparative studies, as demonstrated in HNSCC research where significant differences were observed between tumor and adjacent tissues .

What controls should be included when using HOXA1 antibody for immunohistochemistry?

When performing immunohistochemistry with HOXA1 antibodies, multiple controls are essential for result validation. First, include negative controls by omitting the primary antibody to assess non-specific binding of the secondary antibody. Second, use isotype controls matching the primary antibody's host species and immunoglobulin subclass. Third, include tissue samples known to express varying levels of HOXA1 as positive controls and comparative references. For quantification, analyze both the percentage of HOXA1-positive cells and the HOXA1-positive area as demonstrated in HNSCC research . The numerical dimensions reported in HNSCC studies showed HOXA1-positive area in adjacent tissues was 2.86 ± 1.29 (mean ± SD) compared to 10.44 ± 3.24 in HNSCC tissues (p<0.0001), while HOXA1-positive cells were 16.69 ± 7.60 in adjacent tissues compared to 40.87 ± 11.62 in HNSCC tissues (p<0.0001) .

How should researchers optimize antigen retrieval for HOXA1 immunohistochemistry?

Effective antigen retrieval is crucial for accurate HOXA1 detection in formalin-fixed, paraffin-embedded tissues. Based on published protocols, place sections in 10 mM citrate buffer solution (pH = 6.0) and boil in a pressure cooker for 15 minutes . After cooling to 37°C, treat sections with 3% H₂O₂ for 10 minutes to deplete endogenous peroxidase activity. Blocking with goat serum before primary antibody incubation minimizes non-specific binding. For HOXA1 staining, an anti-HOXA1 polyclonal antibody at 1:100 dilution (such as Thermo Fisher Scientific, catalog # PA5-36164) incubated overnight at 4°C has been validated in research studies . Following PBS washing, appropriate secondary antibody application and visualization systems should be employed based on the experimental design and detection method.

What scoring methods are appropriate for evaluating HOXA1 expression in tissue samples?

For consistent and reproducible evaluation of HOXA1 expression in tissue samples, implement a systematic scoring method assessed by experienced pathologists. One validated approach categorizes HOXA1 protein staining based on the percentage of positive nuclear cells: negative (0–25%), low positive (26–50%), and high positive (51–100%) . For analytical purposes, these can be consolidated into low expression (negative to low positive) and high expression (high positive) groups. Digital image analysis using software like ImageJ can provide objective quantification of staining intensity and distribution. For statistical robustness, multiple fields per slide should be analyzed at standardized magnification (e.g., 200×), and scoring should be conducted by at least two independent observers using single-blind trial techniques to minimize bias .

How can HOXA1 antibodies be used to investigate its role as a prognostic biomarker in cancer?

To investigate HOXA1 as a prognostic biomarker, researchers should implement a multi-phase approach. First, analyze HOXA1 expression in paired tumor and adjacent normal tissues using immunohistochemistry with validated antibodies . Calculate the percentage of HOXA1-positive cells and area measurements to establish quantitative differences. Second, perform correlation analyses between HOXA1 expression levels and clinicopathological features such as tumor stage, grade, and patient outcomes. In HNSCC research, high HOXA1 expression correlated with poor pathological grade (p=0.0077), advanced T stage (p=0.021), and perineural invasion (p=0.0019) . Third, validate prognostic significance through univariate and multivariate Cox regression analyses to determine independent predictive power. Finally, investigate the underlying molecular mechanisms through genomic and transcriptomic analyses such as Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) to identify HOXA1-associated signaling pathways .

What is the relationship between HOXA1 expression and immune cell infiltration in tumors?

The relationship between HOXA1 expression and tumor immune microenvironment can be investigated using complementary approaches. TIMER (Tumor Immune Estimation Resource) analysis has demonstrated that high HOXA1 expression is significantly associated with decreased CD8+ T cell infiltration in head and neck squamous cell carcinoma . This finding was further validated using CIBERSORT analysis, which showed negative correlations between HOXA1 expression and proportions of CD8+ T cells, naïve B cells, CD4 memory activated T cells, and follicular helper T cells, while a positive correlation was observed with M0 macrophages . To investigate this relationship in your research, perform immunohistochemical staining of serial tissue sections for HOXA1 and immune cell markers, or conduct flow cytometry of dissociated tumor samples to correlate HOXA1 expression with immune cell populations. RNA sequencing data can be analyzed through platforms like CIBERSORT to estimate immune cell fractions in relation to HOXA1 expression levels, providing insights into potential immunosuppressive mechanisms .

How does HOXA1 expression correlate with DNA methylation patterns in cancer?

To investigate the relationship between HOXA1 expression and DNA methylation, researchers can utilize integrated analysis of gene expression and methylation data. Studies using the MEXPRESS database have revealed that high HOXA1 expression is associated with decreased promoter methylation in tumor samples, with Pearson correlation coefficients ranging from -0.166 to -0.528 for promoter region probes . Specific probes such as cg03116258, cg07450037, and cd12686016 on chromosome 7 showed the strongest correlation with HOXA1 DNA methylation . To explore this relationship in your research, perform integrated analysis of RNA-seq data (for expression) and methylation arrays (450K or EPIC) from the same samples. Alternatively, targeted approaches such as bisulfite sequencing of the HOXA1 promoter region combined with qRT-PCR or Western blot for expression analysis can be employed. These analyses can provide insights into epigenetic regulation of HOXA1 in cancer and its potential contribution to oncogenic functions.

What signaling pathways are associated with HOXA1 function in cancer progression?

HOXA1's role in cancer progression involves multiple signaling pathways that can be investigated using pathway analysis tools. GSVA and GSEA analyses of HNSCC samples identified fourteen mutual signaling pathways associated with HOXA1 expression, including neuroprotein secretion and transport, tumor-associated signaling pathways, cell adhesion junction, and metabolic reprogramming . To investigate these pathways in your research, perform RNA-seq or microarray analysis comparing high and low HOXA1-expressing samples, followed by pathway enrichment analysis using platforms such as GSEA with MSigDB gene sets. Validation of key pathway components should be conducted through protein expression analysis (Western blot, immunohistochemistry) and functional studies using pathway inhibitors or genetic manipulation approaches. For GSEA implementation, use annotated gene sets such as c2.cp.kegg.v7.1.symbols with parameters including 1,000 permutations and results filtered by normalized enrichment scores (NES), nominal p-value, and false discovery rate (FDR) q-value .

How can researchers investigate the mechanisms behind HOXA1's role in immune escape and oxidative stress in cancer?

HOXA1 has been implicated in facilitating immune escape and alleviating oxidative stress in lung adenocarcinoma (LUAD) . To investigate these mechanisms, researchers should implement a multi-faceted approach. First, establish in vitro models with HOXA1 overexpression or knockdown in cancer cell lines to assess changes in oxidative stress markers (ROS levels, antioxidant enzymes) and immune-related molecules (PD-L1, IDO1, cytokines). Second, perform co-culture experiments with immune cells (T cells, macrophages) and cancer cells with modulated HOXA1 expression to evaluate immune cell function and activation. Third, analyze patient samples for correlations between HOXA1 expression, oxidative stress markers, and immune cell infiltration or activation status. RNA-seq and proteomics analyses of HOXA1-modulated cells can identify key downstream effectors mediating these processes. Finally, in vivo models with immune-competent mice can validate the role of HOXA1 in tumor immune evasion and response to immunotherapy or oxidative stress-inducing treatments .

What therapeutic implications does HOXA1 research have for cancer treatment strategies?

HOXA1 research has revealed significant therapeutic implications for cancer treatment strategies. The high expression of HOXA1 in multiple cancer types and its correlation with poor prognosis suggest its potential as a therapeutic target . Preliminary studies using HOXA1 small interfering RNA (siRNA) nanoparticles have shown promising results in mouse models of breast cancer, with a 75% reduction in tumor incidence . Based on HOXA1's role in immune escape, combination therapies targeting HOXA1 alongside immune checkpoint inhibitors may enhance immunotherapy efficacy, particularly in patients with high HOXA1 expression . The association between HOXA1 and DNA methylation suggests potential synergy with epigenetic therapies such as DNA methyltransferase inhibitors . For researchers exploring therapeutic applications, in vitro drug screening using HOXA1-expressing cell lines, patient-derived xenografts, and syngeneic mouse models can evaluate both direct HOXA1 targeting strategies and combination approaches with established cancer therapies.

What factors affect HOXA1 antibody specificity and how can they be addressed?

Multiple factors can affect HOXA1 antibody specificity in experimental applications. First, antibody source and production method (monoclonal vs. polyclonal) influence specificity—polyclonal antibodies like the mouse polyclonal anti-HOXA1 antibody provide broader epitope recognition but may have more cross-reactivity . Second, sample preparation conditions including fixation method and duration, tissue processing, and antigen retrieval protocol significantly impact epitope accessibility. Third, blocking conditions and antibody dilution must be optimized for each tissue type and application. To address these factors: (1) validate antibody specificity using positive and negative control tissues/cells, (2) include appropriate isotype controls, (3) test multiple antibody dilutions to determine optimal signal-to-noise ratio, (4) compare results across multiple antibodies targeting different HOXA1 epitopes when possible, and (5) consider complementary detection methods (e.g., RNA analysis) to confirm expression patterns observed with antibody-based techniques.

How should researchers design experiments to investigate HOXA1's role in developmental versus oncogenic contexts?

Investigating HOXA1's dual roles in development and oncogenesis requires carefully designed experimental approaches that distinguish between these contexts. For developmental studies, employ model systems such as embryonic stem cells or embryonic tissues during different developmental stages to track spatiotemporal HOXA1 expression patterns using HOXA1 antibodies for immunohistochemistry or immunofluorescence . Time-course experiments with HOXA1 antibody staining can reveal dynamic expression changes during development. For oncogenic context studies, compare HOXA1 expression between matched tumor-normal pairs across multiple cancer types, as demonstrated in HNSCC research where significant upregulation was observed in tumor tissues . Functional studies using HOXA1 overexpression or knockdown in normal versus cancer cell lines can reveal context-dependent effects on proliferation, apoptosis, migration, and other cancer hallmarks. Single-cell analysis techniques combining HOXA1 antibody staining with other markers can reveal cell type-specific expression patterns in heterogeneous tissues. These comparative approaches can identify shared and distinct molecular partners and regulatory mechanisms in developmental versus oncogenic contexts.

What experimental design considerations are important when investigating HOXA1's interaction with other transcription factors?

Investigating HOXA1's interactions with other transcription factors such as PBX1A and PKNOX1 requires sophisticated experimental designs . First, co-immunoprecipitation (Co-IP) experiments using HOXA1 antibodies can identify protein-protein interactions in cell lysates, with reciprocal Co-IPs (pulling down with PBX1A/PKNOX1 antibodies and blotting for HOXA1) providing validation. Second, proximity ligation assays (PLA) using HOXA1 antibodies paired with antibodies against potential binding partners can visualize and quantify interactions in situ with subcellular resolution. Third, chromatin immunoprecipitation (ChIP) with HOXA1 antibodies followed by sequential ChIP (re-ChIP) with antibodies against partner transcription factors can identify co-occupied genomic regions. Fourth, reporter gene assays comparing HOXA1 alone versus HOXA1 with potential partners can assess functional cooperation in transcriptional regulation. Finally, CRISPR-Cas9 manipulation of binding domains can validate the specificity and functional significance of observed interactions. Throughout these experiments, careful consideration of cell type selection, protein expression levels, and antibody compatibility is essential for meaningful results.